HRMY logo

HARMONY BIOSCIENCES HOLDINGS

HRMYNASDAQ
🏆 #1888 by market capEarnings Nov 2US Equity
$276.59▼ $5.84 (−2.11%)
Simulated price
🔔
Track HRMY
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.32B
Small Cap
📈Revenue Growth (YoY)
+21.5%
Healthy
📊Gross Margin
75.4%
High
💵FCF Margin
37.0%
Strong
⚖️P/S Ratio
2.4x
Cheap
Otter Score
68
Fair
No chart data available for HRMY.

Trading Snapshot

Day Range
$275.02 – $281.13
52-Week Range
$25.52 – $43.49
Volume
$1.83B
Avg Volume
$1.59B
Shares Outstanding
57.9M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$868M
Last Q Revenue
$261M
P/E Ratio
12.8
P/S Ratio
2.4x
EPS (TTM)
$3.13
Dividend Yield
0.00%
Dilution (1yr)
+0.8%

Why Investors Own HRMY

  • ✓High-growth profile — revenue up +53.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 35% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HRMY logo

HARMONY BIOSCIENCES HOLDINGS

HRMY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$868M▲ +21.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
77.2%▼ −1.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$208M▲ +9.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$348M▲ +59.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
58.7M▲ +0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$513M▲ +$241M YoY
StockOtter · stockotter.space

About HARMONY BIOSCIENCES HOLDINGS

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$308.98
▲ +11.7% Upside
High Target$343.21
Low Target$235.97
Based on 17 analysts

Latest News & Updates

🚀
Barron’s·2h ago

HARMONY BIOSCIENCES HOLDINGS tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift HRMY price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

HARMONY BIOSCIENCES HOLDINGS announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.